Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Short term Debt: 2014-2016

Historic Short term Debt for KalVista Pharmaceuticals (KALV) over the last 1 years, with Mar 2016 value amounting to $1.9 million.

  • KalVista Pharmaceuticals' Short term Debt rose 81.40% to $1.9 million in Q1 2016 from the same period last year, while for Mar 2016 it was $1.9 million, marking a year-over-year increase of 81.40%. This contributed to the annual value of $127,000 for FY2016, which is N/A change from last year.
  • According to the latest figures from Q1 2016, KalVista Pharmaceuticals' Short term Debt is $1.9 million, which was up 34.02% from $1.5 million recorded in Q4 2015.
  • KalVista Pharmaceuticals' Short term Debt's 5-year high stood at $4.4 million during Q4 2014, with a 5-year trough of $480,000 in Q2 2015.
  • In the last 3 years, KalVista Pharmaceuticals' Short term Debt had a median value of $1.3 million in 2015 and averaged $1.7 million.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Short term Debt slumped by 67.19% in 2015, and later spiked by 81.40% in 2016.
  • Quarterly analysis of 3 years shows KalVista Pharmaceuticals' Short term Debt stood at $4.4 million in 2014, then plummeted by 67.19% to $1.5 million in 2015, then spiked by 81.40% to $1.9 million in 2016.
  • Its Short term Debt stands at $1.9 million for Q1 2016, versus $1.5 million for Q4 2015 and $965,000 for Q3 2015.